Improved outlook for immune-based therapies

July 03, 2013

The idea of fighting infections and even cancers by inducing protective immune responses may now be a step closer to clinical practice. Researchers have removed a major obstacle to widespread use of so-called adoptive transfer therapy, in which a patient receives "killer" immune cells targeting a disease agent. Existing technologies can easily provide T cells that will recognize a specific antigen, but it has been challenging to identify individual cells most likely to succeed in fighting the disease - until now.

Scientists at the Technische Universitaet Muenchen (TUM) have developed the first assay for living T cells that can quantify how strongly the cells' receptors bind to their targeted antigen. Optimal binding strength or "structural avidity" is thought to be the most important predictor of success in adoptive transfer therapies. Together with collaborators in Seattle, Mainz, and Berlin, the TUM researchers have successfully tested their assay in preclinical animal models very close to clinical settings and with human T cells. They published their results in the journal Science Translational Medicine.

A new key to predictability

There are countless kinds of T cells, each one expressing a single type of receptor -- a surface structure capable of locking onto a particular ligand molecule that may, for example, be associated with a virus or a tumor. If a patient's immune system cannot mount an effective defense, it may be possible to fight the disease by introducing the right kind of T cell, either prepared from the patient's own cells or obtained from a donor.

But in a population of T cells equipped to recognize a particular antigen, individual T cells can vary greatly in structural avidity. A main determinant of a T cell's binding strength is the so-called "off rate" -- simply put, a slower off rate indicates stronger binding -- which thus predicts its likely fitness for use in adoptive transfer therapy. And that is what the TUM assay measures, directly and precisely.

The TUM technology offers three marked advantages over previous methods: It is (relatively) simple; it can be used on the surface of living T cells without harming or changing them; and it gives, for the first time, a quantitative measure of binding strength. "This is a true value that we can repeat, and we can compare individual cells on the basis of these measurements," explains Prof. Dirk Busch, director of the TUM Institute for Medical Microbiology, Immunology, and Hygiene. "Furthermore, we now have been able to show that there is indeed a correlation between these values and what the cells can do when we put them into a clinically relevant setting."

Bridging the distance from the labs to the clinic

The Munich-based team had been working on this technology and the underlying scientific questions for nearly a decade before making one crucial connection -- to Seattle. With support from the TUM Institute for Advanced Study, a bridge was formed between Busch's labs and those of Prof. Stanley Riddell, a faculty member at both the Fred Hutchinson Cancer Research Center and the University of Washington.

A pioneer in cell-based therapy, Riddell had been looking for new ways to achieve higher quality and purity in cells for clinical use. Busch was seeking a partner with top-level expertise in human cell-therapy research, trials, and treatment. Together, they developed a close-knit collaboration across nine time zones that transformed both laboratories. Over the course of three years, Riddell spent months in Munich and hosted a number of Busch's postdocs and doctoral candidates, including some of the authors of the current paper, in Seattle. Weekly video conferences filled in the gaps.

As Busch describes it, though, the most significant gap they bridged was the distance from the labs to the clinic. "Stan taught us a lot about how to work with human T cells," he says, "and a lot of the data in this paper, in particular the data on human T cells, is a direct result of our TUM-IAS focus group on clinical cell processing and purification." He is optimistic about the prospects for the T-cell selection assay to play a role in clinical trials and ultimately in therapies, as well as in helping to address critical open questions about immune responses to major diseases.

"Immunotherapy is now beginning to have a major impact for patients with cancer and infectious diseases," Riddell says. "This work provides a novel approach for evaluating the qualities of T cells that may be used for cellular immunotherapy, and it facilitates the selection of those T cells that would be most effective in treating disease."
-end-
This research was supported by the German Research Foundation (DFG) through Collaborative Research Centers SFB TR36 (TP-B10/13), SFB 1054 (TP-B09), and SFB 490 (TP-E3), and through a DFG grant from the Clinical Research Group KFO 183 (individual project TP8), as well as by the TUM Institute for Advanced Study (Focus Group: Clinical Cell Processing and Purification).

Publication:

TCR-ligand k-off rate predicts protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Magdalena Nauerth, Bianca Weissbrich, Robert Knall, Tobias Franz, Georg Doessinger, Jeanette Bet, Paulina J. Paszkiewicz, Lukas Pfeifer, Mario Bunse, Wolfgang Uckert, Rafaela Holtappels, Dorothea Gillert-Marien, Michael Neuenhahn, Angela Krackhardt, Matthias J. Reddehase, Stanley R. Riddell, and Dirk H. Busch. Science Translational Medicine 2013, vol. 5, issue 192. DOI: 10.1126/scitranslmed.3005958

Contact:

Prof. Dirk Busch
Institute for Medical Microbiology, Immunology, and Hygiene
Technische Universität München
T: +49 (0)89 4140-4120
E: dirk.busch@mikrobio.med.tum.de
W: http://www.mikrobio.med.tu-muenchen.de

Technische Universitaet Muenchen (TUM) is one of Europe's leading universities. It has roughly 500 professors, 9,000 academic and non-academic staff, and 32,000 students. It focuses on the engineering sciences, natural sciences, life sciences, medicine, and economic sciences. After winning numerous awards, it was selected as an "Excellence University" in 2006 and 2012 by the Science Council (Wissenschaftsrat) and the German Research Foundation (DFG). In both international and national rankings, TUM is rated as one of Germany's top universities. TUM is dedicated to the ideal of a top-level research-oriented entrepreneurial university. The university's global presence includes offices in Beijing (China), Brussels (Belgium), Cairo (Egypt) and Sao Paulo (Brazil). The German Institute of Science and Technology (GIST), founded in 2002 in Singapore, is the first research campus of a German university abroad. http://www.tum.de

Technical University of Munich (TUM)

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.